FDA Approves Lilly’s Taltz for Psoriasis

Eli Lilly and Co.'s new injectable psoriasis treatment Taltz (ixekizumab) got the thumbs up from the FDA March 22.

In a press release, the FDA said it approved Taltz to treat adults with moderate-to-severe plaque psoriasis.

Taltz is administered as an injection, and it is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected), phototherapy (ultraviolet light treatment) or a combination.

Psoriasis, an often itchy skin disorder, is frequently characterized by silvery or white scales and redness, and often runs in families.

“Today’s approval provides ...